ANTI-CD11B MONOCLONAL-ANTIBODY REDUCES ISCHEMIC CELL-DAMAGE AFTER TRANSIENT FOCAL CEREBRAL-ISCHEMIA IN RAT
ANTI-CD11B MONOCLONAL-ANTIBODY REDUCES ISCHEMIC CELL-DAMAGE AFTER TRANSIENT FOCAL CEREBRAL-ISCHEMIA IN RAT
复制标题
DOI：
10.1002/ana.410350414
复制
发表时间：
1994-04-01
影响因子：
11.2
通讯作者：
TODD, RF
中科院分区：
文献类型：
--
作者：
CHEN, H;CHOPP, M;TODD, RF
我们观察了抗CD11b单抗(1B6c)对短暂性大脑中动脉闭塞后缺血细胞损伤的影响。我们将动物分为三组：单抗1组(n=5)-大鼠短暂阻断2小时，在再灌注0和22小时静脉注射1B6c(1 mg/kg)；单抗2组(n=5)-实验方案与单抗1组相同，只是初始剂量为Inc.；对照组(n=5)-实验方案与单抗2组相同，只是给予与单抗2组相同的实验方案。动物在大脑中动脉闭塞前和闭塞后称重并进行神经功能测试。再灌流后46h取脑切片，苏木精-伊红染色进行组织学评价。我们观察到，与单抗1和赋形剂治疗的动物相比，单抗2组动物在缺血后体重减轻和神经功能改善显著减少(p<；0.05)。MAb2组病变体积(19.5+/-1.9%)明显小于MAB1组(29.9+/-2.6%)和赋形剂治疗组(34.2+/-5.4%)(P<；0.01)。两个1B6c组的组织中多形核细胞数量均减少。我们的数据表明，给予抗CD11b抗体可以剂量依赖性地显著改善大鼠短暂性局灶性脑缺血后的功能，并减少缺血细胞的损伤。
We investigated the effect of an anti-CD11b monoclonal antibody (1B6c) on ischemic cell damage after transient middle cerebral artery occlusion. We divided animals into three groups: MAb 1 group (n = 5)-rats were subjected to 2 hours of transient occlusion and 1B6c (1 mg/kg) was administered intravenously at 0 and 22 hours of reperfusion; MAb 2 group (n = 5)-same experimental protocol as MAb 1 group, except that the initial dose of 1B6c was inc;eased to 2 mg/kg; and control group (n = 5)-same experimental protocol as MAb 2 group, except that an isotype-matched control antibody was administered. Animals were weighed and tested for neurological function before and after occlusion of the middle cerebral artery. Forty-six hours after reperfusion, brain sections were stained with hematoxylin and eosin for histology evaluation. We observed a significant reduction of weight loss and improvement in neurological function after ischemia in the MAb 2 animals compared to MAb 1 and vehicle-treated animals (p < 0.05). The lesion volume was significantly smaller in the MAb 2 group (19.5 +/- 1.9%) compared to MAb1 (29.9 +/- 2.6%) and vehicle-treated (34.2 +/- 5.4%) groups (P < 0.01). Tissue polymorphonuclear cell numbers were reduced in both 1B6c-administered groups. Our data demonstrate that administration of anti-CD11b antibody results in a dose-dependent, significant functional improvement and reduction of ischemic cell damage after transient focal cerebral ischemia in the rat.